Inter-laboratory comparison of a serum fibroblast growth factor receptor 3 (FGFR3) antibody test in sensory neuropathies
Frontiers in Immunology · 2025
DOI: 10.3389/fimmu.2025.1604456 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Frontiers in Immunology, 2025. Verfasst von Luise Appeltshauser und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 3, Autoantibodies, Small Fiber Neuropathy, Peripheral Nervous System Diseases. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Autoantibodies against fibroblast growth factor receptor 3 (FGFR3) have been suggested as a diagnostic marker in both sensory large and small fiber neuropathy. Yet, their clinical relevance remains unclear and no standardized protocols for antibody testing exist. Here, we evaluate an anti-FGFR3 ELISA protocol in an inter-laboratory comparison.
Methods
We performed anti-FGFR3 ELISA on 42 serum samples of patients with sensory neuronopathy (n = 18), small fiber neuropathy (n = 18), and healthy controls (n = 6) in two independent centers in France (center 1) and Germany (center 2) using identical protocols, with double immunofluorescence staining on rat dorsal root ganglion (DRG) sections as a confirmational test.
Results
Overall ELISA concordance was 34/42 (81.0%, Cohen’s kappa = 0.61, substantial agreement). Discordance occurred for sera with optical densities (OD) near the cut-off. ODs correlated (r = 0.68, p < 0.0001), but were lower at center 2 (median = 0.076 vs 0.293, p < 0.0001), indicating that cut-off values are laboratory-specific. 11/16 (68.8%) ELISA-double-positive sera stained small DRG neurons, colocalizing with commercial anti-FGFR3 antibody, while positive binding was only found in 1/20 (5%) of ELISA-negative sera (p < 0.0001). DRG-positive samples showed higher ODs than negative ones (p < 0.0001).
Discussion
We provide and evaluate a detailed ELISA protocol for anti-FGFR3 diagnostic assessment. Positive results near the threshold should be interpreted cautiously. Anti-FGFR3 DRG staining may be a useful confirmatory method and could increase diagnostic specificity. This study facilitates future studies on the diagnostic relevance of anti-FGFR3 autoantibodies in sensory neuropathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University Hospital Würzburg, Würzburg, Germany.
- Department of Neurology, CHU Saint-Etienne, Saint-Etienne, France.
- Synaptopathies et autoanticorps (SynatAc), Institut MELIS-NeuroMyoGène, INSERM U1314/CNRS UMR 5284, Université Jean Monnet, Saint-Étienne, France.
- Department of Biochemistry, CHU Saint-Etienne, Saint-Etienne, France.
Zitieren
APA
Appeltshauser, L., Moritz, C. P., Reinhardt, L., Kreß, L., Üçeyler, N., Lassablière, F., Barcic, A., Seefried, S., Sommer, C., Tholance, Y., Antoine, J. C., Camdessanché, J. P., & Doppler, K. (2025). Inter-laboratory comparison of a serum fibroblast growth factor receptor 3 (FGFR3) antibody test in sensory neuropathies. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1604456
Vancouver
Appeltshauser L, Moritz CP, Reinhardt L, Kreß L, Üçeyler N, Lassablière F, et al. Inter-laboratory comparison of a serum fibroblast growth factor receptor 3 (FGFR3) antibody test in sensory neuropathies. Frontiers in Immunology. 2025. doi:10.3389/fimmu.2025.1604456
BibTeX
@article{Appeltshauser2025,
author = {Appeltshauser, Luise and Moritz, Christian P and Reinhardt, Lena and Kreß, Luisa and Üçeyler, Nurcan and Lassablière, François and Barcic, Anastasia and Seefried, Sabine and Sommer, Claudia and Tholance, Yannick and Antoine, Jean-Christophe and Camdessanché, Jean-Philippe and Doppler, Kathrin},
title = {Inter-laboratory comparison of a serum fibroblast growth factor receptor 3 (FGFR3) antibody test in sensory neuropathies},
journal = {Frontiers in Immunology},
year = {2025},
doi = {10.3389/fimmu.2025.1604456}
}
EUVIMED